相关实验视频

Updated: Jun 16, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

疾病在6个月内进展:对ENKTL的早期疾病进展值进行了修订

Miao Zhong¹, Hailing Liu¹, Renfu Gui¹

¹Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.

Leukemia & lymphoma

|June 11, 2025

概括

疾病在6个月内进展 (POD6) 是外节NK/T细胞淋巴瘤 (ENKTL) 的关键早期指标. POD6有效地预测了长期生存,为这种攻击性淋巴瘤提供了有价值的预后工具.

科学领域:

血液学血液学血液学
在瘤学瘤学.
淋巴瘤研究淋巴瘤研究

背景情况:

24个月内的疾病进展 (POD) 是淋巴瘤的已知预后因素.
外节NK/T细胞淋巴瘤 (ENKTL) 是一种侵略性淋巴瘤,需要更短的预后评估期.

研究的目的:

评估早期疾病进展 (POD) 度量作为外节NK/T细胞淋巴瘤 (ENKTL) 的预后指标的实用性.
确定较短的评估期,特别是6个月内的POD (POD6),是否可以预测ENKTL患者的整体存活率 (OS).

主要方法:

对170名新诊断的ENKTL患者进行了回顾性分析,这些患者接受了基于阿斯巴拉金酶的治疗方案.
患者根据复发/进展被分为三个组:POD6,POD6-24和POD>24个月.
考克斯回归分析用于确定整体存活时间的独立风险因素.

主要成果:

POD6组的平均整体存活 (OS) 为16.5个月;POD6-24和POD>24组没有达到OS.
在POD6和POD24患者中,生存结果是可比的.
POD6被确定为OS的独立风险因素,无论传统的风险分层如何.

结论:

疾病在6个月内进展 (POD6) 是ENKTL的早期预后标志物.
在涉及ENKTL的临床研究中,POD6作为长期预后的可靠替代品.
早期评估疾病进展对于管理像ENKTL这样的侵袭性淋巴瘤至关重要.

关键词:

额外的NK/T细胞淋巴瘤.这是早期进展的早期进展.结果结果结果结果.预测性表现的预测性表现.替代体标志物替代体标志物

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...